| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H14N2O |
| Molecular Weight | 238.2845 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(C)=C(N1)\C=C2/C(=O)NC3=C2C=CC=C3
InChI
InChIKey=WUWDLXZGHZSWQZ-WQLSENKSSA-N
InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
| Molecular Formula | C15H14N2O |
| Molecular Weight | 238.2845 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Semaxanib is a potent and selective vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor that also inhibits other tyrosine kinases KIT, MET, FLT3, and RET. Semaxanib inhibited cell migration of human vascular endothelial cells expressing both Flt-1 and KDR in response to VEGF and also inhibited the cell migration in response to placenta growth factor (PIGF), a specific ligand for Flt-1. Chemotaxis of monocytes expressing only Flt-1 was also inhibited by SU5416 in a dose-dependent manner. Semaxanib targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential. On February 2002, Pharmacia, the then-parent of Sugen, prematurely ended Phase III clinical trials of Semaxinib in the treatment of advanced colorectal cancer due to discouraging results.
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
145 mg/m2 intravenously twice-weekly in combination with thalidomide, commencing at 200 mg daily with intrapatient dose escalation as tolerated
Route of Administration:
Intravenous
Cells (HMEC-1, BAEC, HELA or MCF-7) were seeded in 48-well plates at 10,000 cells per cm2. After 16 h, the cells were incubated in fresh medium in the presence of the test compounds (Semaxanib 1-100mkM). On day 4, (BAEC, HELA, MCF-7) or day 7 (HMEC-1) cells were trypsinized and counted by means of a Coulter counter (Analis, Belgium). For each compound, the IC50 value was determined.
